- IGC Pharma (IGC, Financial) expands the CALMA trial to Oklahoma, diversifying its trial population.
- The new clinical trial site at Tekton Research will be led by neurologist Dr. David McCoy.
- The trial focuses on the cannabinoid-based therapy IGC-AD1 for Alzheimer's-related agitation.
IGC Pharma, Inc. (IGC) has announced the expansion of its Phase 2 clinical trial, CALMA, evaluating the efficacy of IGC-AD1 for addressing agitation in Alzheimer's dementia. The expansion includes a new trial site at Tekton Research in Yukon, Oklahoma, and is led by Dr. David McCoy, a board-certified neurologist and principal investigator.
The addition of the Oklahoma site aims to diversify the trial population and address regional healthcare disparities within the Oklahoma City metropolitan area. IGC Pharma's strategy involves reaching broader demographics essential for developing effective treatments for Alzheimer's-related agitation.
Tekton Research, experienced in conducting clinical trials across therapeutic areas such as Alzheimer's disease, migraine, and vaccines, is now open for patient enrollment at the Yukon facility. Patients and caregivers interested in participating can contact Tekton Research at 1804 Commons Circle, Suite B, Yukon, OK 73099, call (405) 594-7712, or email [email protected].
The CALMA trial is a multicenter, double-blind, randomized, placebo-controlled study designed to evaluate the safety and efficacy of IGC-AD1, a cannabinoid-based therapy. IGC-AD1 acts as a partial CB1 receptor agonist, addressing pathways related to neuroinflammation and neurotransmitter imbalances, conditions prevalent in Alzheimer's-related agitation, which affects up to 76% of patients.
For further details on the CALMA trial and participation, visit ClinicalTrials.gov.
